US Stock MarketDetailed Quotes
HOOK HOOKIPA Pharma
- 4.880
- +0.110+2.31%
Close Aug 15 16:00 ET
48.29MMarket Cap-1184P/E (TTM)
5.010High4.740Low33.78KVolume4.760Open4.770Pre Close164.67KTurnover0.73%Turnover RatioLossP/E (Static)9.89MShares11.30052wk High0.56P/B22.56MFloat Cap4.10052wk Low--Dividend TTM4.62MShs Float200.000Historical High--Div YieldTTM5.66%Amplitude4.100Historical Low4.874Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
HOOKIPA Pharma Stock Forum
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split - July 10,2024
Ladies and gentleman, On the 17 June 2024, 5 directors and 1 chairperson have collectively bought over 340K of shares at around 0.71 $.
Just wanted to share .... 😊
Up down up down, these shorties will never let us live in peace 🤬🤬🤬
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...
No comment yet